RhumbLine Advisers
CLYM

RhumbLine Advisers’s Climb Bio CLYM Stock Holding History

RhumbLine Advisers’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$581K Buy
+44,544
New +$460K ﹤0.01% 2672
2025
Q2 		– Sell
-24,782
Closed -$30.2K – 4294
2025
Q1 		$30.2K Sell
24,782
-7,054
-22% -$11.4K ﹤0.01% 3671
2024
Q4 		$57.3K Buy
31,836
+4,096
+15% +$14.8K ﹤0.01% 3622
2024
Q3 		$141K Buy
27,740
+19,507
+237% +$138K ﹤0.01% 3392
2024
Q2 		$58.5K Buy
+8,233
New +$54.8K ﹤0.01% 3646

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RhumbLine Advisers's CLYM Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Climb Bio (CLYM) in Q2 2026: 44,544 shares worth $581K. The stake represents ﹤0.01% of the portfolio and ranks #2672 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in CLYM as recently as Q1 2025.

RhumbLine Advisers first reported a position in CLYM in Q2 2024 and has held it in 5 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • RhumbLine Advisers held 44,544 shares of Climb Bio worth $581K as of Q2 2026.
  • Climb Bio was a new RhumbLine Advisers position in Q2 2026.
  • Climb Bio made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2672 holding.
  • RhumbLine Advisers first reported a position in Climb Bio in Q2 2024 and has held it in 5 quarters since.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.